Epidemiology of Myelodysplastic Syndromes

被引:148
|
作者
Ma, Xiaomei [1 ,2 ]
机构
[1] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT USA
来源
AMERICAN JOURNAL OF MEDICINE | 2012年 / 125卷 / 07期
关键词
Incidence; Myelodysplastic syndromes; Prevalence; Prognosis; UNITED-STATES; RISK-FACTORS; SCORING SYSTEM; SURVIVAL; OLDER;
D O I
10.1016/j.amjmed.2012.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem cell malignancies with significant morbidity and high mortality. The incidence of MDS increases markedly with age, and the disease is most prevalent in individuals who are white and male. It is conservatively estimated that >10,000 new cases of MDS occur in the United States annually, and that >= 60,000 individuals with MDS currently reside in the country. With an aging population and an improving awareness of the disease, the documented disease burden is expected to escalate in the near future. Recent studies have identified new or inconsistent etiologic factors that warrant further research. Given the poor survival of individuals with MDS, it is important to identify prognostic factors to better risk-stratify patients for more effective treatment. The relevance of different comorbidities to MDS prognosis and the potential interaction between various comorbidities represents an interesting area of research. (C) 2012 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2012) 125, S2-S5
引用
收藏
页码:S2 / S5
页数:4
相关论文
共 50 条
  • [31] Progress in Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S286 - S292
  • [32] Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
    Kasprzak, Annika
    Nachtkamp, Kathrin
    Gattermann, Norbert
    Germing, Ulrich
    CANCERS, 2022, 14 (08)
  • [33] Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes
    Cazzola, Mario
    Malcovati, Luca
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 459 - +
  • [34] Risk factors and their relationship to prognosis in myelodysplastic syndromes
    Greenberg, PL
    LEUKEMIA RESEARCH, 1998, 22 : S3 - S6
  • [35] The incidence of myelodysplastic syndromes in Western Greece is increasing
    Avgerinou, Christina
    Alamanos, Yannis
    Zikos, Panagiotis
    Lampropoulou, Polyxeni
    Melachrinou, Maria
    Labropoulou, Vassiliki
    Tavernarakis, Ioannis
    Aktypi, Anthi
    Kaiafas, Panagiotis
    Raptis, Christos
    Kouraklis, Alexandra
    Karakantza, Marina
    Symeonidis, Argiris
    ANNALS OF HEMATOLOGY, 2013, 92 (07) : 877 - 887
  • [36] Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes
    Foran, James M.
    Shammo, Jamile M.
    AMERICAN JOURNAL OF MEDICINE, 2012, 125 (07): : S6 - S13
  • [37] Editorial: Risk-stratification in myelodysplastic syndromes
    Breccia, Massimo
    Vinchi, Francesca
    Bonifacio, Massimiliano
    Binotto, Gianni
    Zheng, Gang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Myelodysplastic syndromes - Incidence and survival in the United States
    Ma, Xiaomei
    Does, Monique
    Raza, Azra
    Mayne, Susan T.
    CANCER, 2007, 109 (08) : 1536 - 1542
  • [39] Myelodysplastic syndromes: A practical approach to diagnosis and treatment
    Barzi, Afsanen
    Sekeres, Mikkael A.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2010, 77 (01) : 37 - 44
  • [40] The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands
    Dinmohamed, Avinash G.
    van Norden, Yvette
    Visser, Otto
    Posthuma, Eduardus F. M.
    Huijgens, Peter C.
    Sonneveld, Pieter
    de Loosdrecht, Arjan A. van
    Jongen-Lavrencic, Mojca
    LEUKEMIA RESEARCH, 2015, 39 (02) : 177 - 182